Voyager (VYGR) Exercises Options to Use REGENXBIO’s (RGNX) NAV Vectors
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) and REGENXBIO Inc. (Nasdaq: RGNX) announced that Voyager has exercised commercial options for the use of REGENXBIO’s NAV vectors for the development and commercialization of gene therapies for specific neurological diseases.
Upon exercise of the options, REGENXBIO has granted Voyager a non-exclusive worldwide commercial license, with rights to sublicense, to three specific NAV vector sequences covered by REGENXBIO’s NAV Technology Platform, each for the treatment of a specific neurological disease. In return for these rights, REGENXBIO will receive undisclosed upfront payments, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.
“Today’s announcement aligns with our stated goal of advancing our multiple preclinical programs during this year and into 2017 towards selection of lead clinical candidates,” said Steven Paul, M.D., President and Chief Executive Officer of Voyager Therapeutics. “Exercising the commercial options with REGENXBIO represents an important step for our preclinical pipeline programs, and we are excited with the progress of our continued collaboration with REGENXBIO.”
“These option exercises serve as further validation of our proprietary NAV Technology Platform, the breadth of our intellectual property portfolio, and the unique properties of NAV vectors for targeting the central nervous system and a number of other organ systems,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “As a leader in next-generation AAV gene therapy, REGENXBIO is pleased to continue our collaboration with Voyager and its pursuit of developing and delivering life-changing treatments for severe diseases of the CNS.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- bluebird bio (BLUE) Names New COO and New SVP of Europe
- Neovasc (NVCN) Agrees to Sell Tissue Processing Tech to Boston Scientific (BSX) in $75M Deal
- Franklin Street Properties (FSP) Acquires Denver-Located Dominion Towers
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!